Biosimilars in the EU: cutting through the hype
In April, the European Medicines Agency’s (EMA) Executive Director, Guido Rasi, stated that “Today, biosimilars are an integral part of the effective biological therapies available in the EU”, suggesting that the hype is turning into reality. But how much of an impact have biosimilars made to date, and what are the policy implications?
Europe’s year ahead
2017 is set to be a turbulent year in European politics. Elections will shake the Governments of Germany, France, the Netherlands and the Czech Republic and negotiations are likely to get tough over Brexit.
Incisive Health scoops 4 prestigious Communiqué awards
Our team is celebrating following FOUR big wins, including Small and Specialist Consultancy of the Year, at the Communiqué Awards.
Brexit-bound: what happens now?
As the UK decides to leave the EU, Incisive Health considers what the referendum result means for health.